Spravato is a first-of-its-kind medication to ... fall and rise again of Adrien Brody Box Office: Mel Gibson and Mark Wahlberg's ‘Flight Risk' Flies to No. 1 With $12 Million in Yet Another ...

All participants will be in a listen-only mode until the question-and-answer session of the conference. This call is being ...

Investing in dividend aristocrats can form the cornerstone of a reliable investment strategy, owing to their qualities like ...

Dividend growth stocks offer a balance of stability and compounding returns, and here are three standout companies with ...

The drug is available as an intravenous infusion or an intranasal product called Spravato (esketamine ... 23.1081 Fornaro M, Anastasia A, Valchera A, et al. The FDA "black box" warning on ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the immediate impact Spravato has had on patients with treatment-resistant ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the approval of Spravato for treatment-resistant depression. PE: How does ...

Johnson & Johnson's Spravato has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA announced Tuesday.

Drug is the first and only approved monotherapy for refractory major depressive disorder. (HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...

"SPRAVATO ® is now available as a standalone treatment, meaning patients may experience improvements in depressive symptoms as early as 24 hours and at 28 days – without the need for daily oral ...

Parkside Psychiatric Hospital in Tulsa has an on-site Spravato outpatient clinic that sees over 20 patients per week. According to Parkside, these patients are seen at least twice a week for the ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of MDD in those who have not responded to at least two oral antidepressants. Hundreds of ...